Trubion Pharmaceuticals is a technology company.
Trubion Pharmaceuticals has raised $32.0M across 1 funding round.
Trubion Pharmaceuticals has raised $32.0M in total across 1 funding round.
Trubion Pharmaceuticals has raised $32.0M in total across 1 funding round.
Trubion Pharmaceuticals's investors include Acorn Bioventures.
Trubion Pharmaceuticals was a biopharmaceutical company, not a technology company in the modern software or tech startup sense. Founded in 1999, it developed protein-based therapeutic product candidates, including SMIP (small modular immunopharmaceutical) and SCORPION protein therapeutics, targeting autoimmune diseases like rheumatoid arthritis, inflammatory conditions, and cancer.[1][2][3][4] These therapies served patients with hard-to-treat conditions by offering smaller, engineered proteins designed for precise antigen targeting and biological activity similar to monoclonal antibodies (mAbs) but potentially with improved specifications.[1] The company built early momentum through partnerships, such as a 2005 collaboration with Wyeth for CD20-directed therapeutics, before being acquired by Emergent BioSolutions in 2010.[1]
Trubion emerged in 1999 as a spin-off from the Pacific Northwest Diabetes Research Institute in Seattle, Washington, initially as an early-stage development company focused on protein therapeutics.[1][3] It was established in the State of Washington and reincorporated in Delaware in October 2002, going public on Nasdaq under ticker TRBN.[1] Key early traction came from its technology pillars—SMIP proteins (single-chain polypeptides with binding, hinge, and effector domains), SCORPION proteins, and TRU-ADhanCe potency enhancers—aimed at validated antigens for diseases like non-Hodgkin lymphoma and autoimmune disorders.[1][2] A pivotal moment was the 2005 Wyeth agreement for global development and commercialization, which extended research support until 2009, fueling its pipeline before the 2010 acquisition.[1]
Trubion stood out in biopharma through its proprietary protein engineering platforms, distinguishing it from traditional antibody developers:
Trubion rode the early 2000s wave of biologics innovation, particularly the shift from large monoclonal antibodies to engineered protein therapeutics amid rising demand for targeted autoimmune and oncology treatments.[1] Timing was ideal post-genomics era, when antigen validation enabled precise therapies, and market forces like patent cliffs on blockbuster mAbs (e.g., Rituxan) created opportunities for next-gen alternatives.[1] It influenced the Seattle biotech ecosystem as a Venrock-backed player, contributing to the region's growth in protein engineering and spin-offs from research institutes, though its 2010 acquisition by Emergent BioSolutions shifted its tech into larger portfolios for immune therapies.[1][2]
Trubion's story ended with its 2010 acquisition, integrating its SMIP and related platforms into Emergent BioSolutions' arsenal, where elements likely advanced immune and infectious disease programs amid evolving biologics trends.[1] Post-acquisition, its tech influenced glycoscience and glycan-based therapeutics indirectly, as seen in modern advancements in protein glycosylation for stability and targeting—fields Trubion's potency enhancers foreshadowed.[1][5] Looking ahead, Trubion exemplifies how early biotech pioneers fuel incumbents, with its legacy shaping today's precision protein drugs in a market now dominated by bispecifics and ADCs; its influence persists in the continuum from 1990s spin-offs to 2020s glycan innovations, underscoring biopharma's acquisitive ecosystem.
Trubion Pharmaceuticals has raised $32.0M across 1 funding round. Most recently, it raised $32.0M Series B in July 2004.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2004 | $32.0M Series B | Acorn Bioventures |